Enhanced protein kinase B/Akt signalling in pituitary tumours von Muşat, M, Korbonits, M, Kola, B, Borboli, N, Hanson, M R, Nanzer, A M, Grigson, J, Jordan, S, Morris, D G, Gueorguiev, M, Coculescu, M, Basuand, S, Grossman, A B

Volltext

S34 A multi-disciplinary approach ensuring successful transition from paediatric to adult asthma care – a focus on treatment adherence von Stewart-Kelcher, N, d’Ancona, G, Hearn, A, Thomson, L, Fernandes, M, Roxas, C, Iles, R, Gupta, A, Dhariwal, J, Jackson, DJ, Nanzer, AM

Volltext

P42 Asthma treatment adherence checks: present and future von Stewart-Kelcher, N, Patel, A, Rahman, S, Hearn, A, Roxas, C, Green, L, Thomson, L, Fernandes, M, Nanzer, AM, Jackson, DJ, Dhariwal, J, d’Ancona, G

Volltext

P204 COVID-19 in the absence of eosinophils: a case series of confirmed infection whilst on treatment with benralizumab von Francis, CHR, Hearn, AP, Ratnakumar, S, Taylor, A, Duckitt, J, Ahmed, U, Dhariwal, J, Nanzer, AM, Jackson, DJ

Volltext

P116 Factors associated with hospital admission for patients presenting with an acute asthma exacerbation von Kuncewicz, K, Fernandes, M, Thomson, L, Roxas, C, Hearn, A, d’Ancona, G, Dhariwal, J, Jackson, DJ, Nanzer, AM

Volltext

P98 Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis von Nanzer, AM, Dhariwal, J, Kavanagh, J, Hearn, A, Agarwal, S, Thomson, L, Fernandes, M, Roxas, C, Green, L, d’Ancona, G, Kent, BD, Jackson, DJ

Volltext

P107 The impact of anti-IL5/5R biologic therapies on specific domains of the Asthma Control Questionnaire von Rykova, E, Hearn, AP, Kavanagh, J, d’Ancona, G, Fernandes, M, Green, L, Roxas, C, Thomson, L, Dhariwal, J, Nanzer, AM, Jackson, DJ

Volltext

P103 The relationship between FeNO and response to anti-IL5/5R biologic therapies in severe eosinophilic asthma von Hearn, AP, Kavanagh, J, d’Ancona, G, Fernandes, M, Green, L, Roxas, C, Thomson, L, Dhariwal, J, Nanzer, AM, Jackson, DJ

Volltext

Dendritic cell phenotype in severe asthma reflects clinical responsiveness to glucocorticoids von Chambers, E. S., Nanzer, A. M., Pfeffer, P. E., Richards, D. F., Martineau, A. R., Griffiths, C. J., Corrigan, C. J., Hawrylowicz, C. M.

Volltext

S85 Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment von Hearn, AP, Mak, MS, Budaj, I, Qurashi, N, Snell, O, Kavanagh, J, Fernandes, M, Green, L, Roxas, C, Thomson, L, d’Ancona, G, Dhariwal, J, Nanzer, AM, Jackson, DJ

Volltext

S54 Evidence of drug antibody development in severe eosinophilic asthmatics treated with benralizumab von Thomson, L, Kavanagh, J, Green, L, Fernandes, M, Roxas, C, d’Ancona, G, Dhariwal, J, Nanzer, AM, Kent, BD, Jackson, DJ

Volltext

S34 The role of baseline morning cortisol as a guide to assess adrenal failure in severe steroid dependent asthma von Nanzer, AM, Roxas, C, Green, L, Thomson, L, Fernandes, M, Kavanagh, J, d’Ancona, G, Dhariwal, J, Kent, BD, Jackson, DJ

Volltext

P88 Real-world effectiveness of anti-IL-5/5R therapies in severe atopic eosinophilic asthmatics eligible for anti-IgE therapy von Jackson, DJ, Kavanagh, J, Roxas, C, D’Ancona, G, Green, L, Thomson, L, Fernandes, M, Dhariwal, J, Nanzer, AM, Kent, BD

Volltext

S53 Response to benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma von Kavanagh, J, Roxas, C, Green, L, Thomson, L, d’Ancona, G, Fernandes, M, Dhariwal, J, Nanzer, AM, Kent, BD, Jackson, DJ

Volltext

P89 Real-world 1 year effectiveness of benralizumab in severe eosinophilic asthma von Kavanagh, J, Roxas, C, Thomson, L, Fernandes, M, Green, L, d’Ancona, G, Dhariwal, J, Nanzer, AM, Kent, BD, Jackson, DJ

Volltext

P86 Does adherence to ICS/LABA therapy change following initiation of Benralizumab in the treatment of severe asthma and does this affect outcome? von d’Ancona, G, Bains, S, Bakrania, P, Green, L, Fernandes, M, Roxas, C, Thomson, L, Osman, L, Stewart-Knight, K, Dhariwal, J, Nanzer, AM, Kavanagh, J, Jackson, DJ, Kent, BD

Volltext

Influence of a single oral dose of vitamin D2 on serum 25-hydroxyvitamin D concentrations in tuberculosis patients von MARTINEAU, A. R, NANZER, A. M, WILKINSON, R. J, GRIFFITHS, C. J, SATKUNAM, K. R, PACKE, G. E, RAINBOW, S. J, MAUNSELL, Z. J, TIMMS, P. M, VENTON, T. R, ELDRIDGE, S. M, DAVIDSON, R. N

Volltext

Novel molecular aspects of pituitary adenomas von Hubina, E, Ruscica, M, Nanzer, A M, Czirják, S, Góth, M I, Grossman, A B, Korbonits, M

Volltext

P193 A role for active Vitamin D in steroid resistant asthma patients who have enhanced production of IL-17A and reduced IL-10 von Nanzer, AM, Chambers, ES, Richards, DF, Martineau, AR, Griffiths, CJ, Corrigan, C, Hawrylowicz, CM

Volltext

Defining severe asthma - an approach to find new therapies von Nanzer, AM, Menzies-Gow, A

Volltext